Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo-Reference-Cited by-同舟云学术

Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo

Published:2006-04 Issue:2 Volume:8 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Wärnberg Fredrik,White Daniel,Anderson Elizabeth,Knox Fiona,Clarke Robert B,Morris Julie,Bundred Nigel J

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr1395.pdf

Reference46 articles.

1. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999, 17: 3631-3652.

2. Clark GJ, Der CJ: Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat. 1995, 35: 133-144. 10.1007/BF00694753.

3. Dankort DL, Muller WJ: Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene. 2000, 19: 1038-1044. 10.1038/sj.onc.1203272.

4. DeFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL: Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer. 2000, 87: 487-498. 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J.

5. Oehler MK, Rehn M, Kristen P, Sutterlin M, Caffier H: Correlation of the EGF-receptor with cell kinetic and classical prognostic factors in breast cancer. Anticancer Res. 1997, 17: 3137-3140.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishment of a 3D co‐culture model to investigate the role of primary fibroblasts in ductal carcinoma in situ of the breast;Cancer Reports;2022-12-19

2. FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer;Cancers;2022-01-18

3. Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare;Cancers;2020-05-20

4. Therapeutic potential of RAS prenylation pharmacological inhibitors in the treatment of breast cancer, recent progress, and prospective;Journal of Cellular Biochemistry;2018-10-30

5. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors;Investigational New Drugs;2018-08-31